
Bullseye Biosciences develops novel therapeutics by evolving proteins to address hard-to-treat human diseases. The company applies directed evolution combined with laboratory automation, next-generation sequencing, and artificial intelligence to discover and optimize drug candidates. Bullseye operates as a biotechnology drug-discovery firm serving biopharma and healthcare organizations through discovery-stage partnerships and programs. Its focus areas include cardiometabolic diseases, inflammation, and oncology, targeting indications with high unmet medical need.

Bullseye Biosciences develops novel therapeutics by evolving proteins to address hard-to-treat human diseases. The company applies directed evolution combined with laboratory automation, next-generation sequencing, and artificial intelligence to discover and optimize drug candidates. Bullseye operates as a biotechnology drug-discovery firm serving biopharma and healthcare organizations through discovery-stage partnerships and programs. Its focus areas include cardiometabolic diseases, inflammation, and oncology, targeting indications with high unmet medical need.
Headquarters: Pagliuca Harvard Life Lab, Allston, MA
Founding year: 2024
Focus: Directed evolution, automation, NGS, and AI for drug discovery
Seed / fundraising: Pre-Seed round announced Oct 30, 2024 led by Mission BioCapital
Key leaders: Corey Gray (Co‑founder & CEO); Michael McKeown (Co‑founder & Head of Research)
Drug discovery for cardiometabolic, inflammation, and oncology targets
2024
Biotechnology